INFOGRAPHIC: Novartis/GSK/Lilly swapping extravaganza explained
This article was originally published in Scrip
Executive Summary
In the wake of Novartis and GlaxoSmithKline announcing plans to exchange big sectors of their portfolios in a multi-billion dollar mega-deal, and Novartis also shifting off its animal health unit to Eli Lilly in the same breath, Scrip has taken a closer look at who's getting what – cutting down the waffle to the specifics.